ClinicalTrials.gg
CompletedNCT05901831FINE-ONEUpdated Oct 27, 2026Results posted

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

A Phase 3 interventional study of Finerenone and Placebo in Chronic Kidney Disease and Type 1 Diabetes Mellitus, sponsored by Bayer. Completed at 79 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Updated Oct 27, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing finerenone in Renal Insufficiency, Chronic — 14 open to participants now, 16 under way, 4 of them phase 3. finerenone · Renal Insufficiency, Chronic.

Enrollment
6th of 25
242 · median 100
Started
2024
with 4 others
Phase 3
6 of 25
3 open now
Registered
9th of 25
by date
Lead sponsor
8 of 25
Bayer

Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, this one is the 6th largest by enrollment, is one of 5 that started in 2024, is one of 6 in phase 3, and was the 9th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

14 of the 25 studies testing finerenone in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing finerenone in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes.

In people with type 1 diabetes, the body does not make enough of a hormone called insulin, resulting in high blood sugar levels that can cause damage to the kidneys. CKD often occurs together with or as a consequence of type 1 diabetes.

The study treatment finerenone works by blocking certain proteins, called mineralocorticoid receptors. An increased stimulation of these proteins is thought to damage the kidneys and the heart. By lowering their stimulation, finerenone reduces the risk of kidney disease progressively getting worse. Finerenone is approved for doctors to prescribe to people with CKD and type 2 diabetes.

In this study, researchers want to learn if finerenone works better than placebo in reducing the participants' kidney disease from getting worse when given in addition to standard of care (SOC) treatment. A placebo looks like a treatment but does not have any medicine in it. SOC is a procedure or treatment that medical experts consider most appropriate for a condition or disease. To find out how well finerenone works, the level of a protein (albumin) in the urine will be measured.

Researchers also want to know how safe finerenone is. To do this, the researchers will collect the number of participants with:

  • medical problems (also called treatment-emergent adverse events (TEAEs))
  • serious TEAEs. A TEAE is considered 'serious' when it leads to death, puts the participant's life at risk, requires hospitalization, causes disability, causes a baby being born with medical problems, or is medically important
  • higher than normal blood levels of potassium (hyperkalaemia). Depending on the treatment group, the participants will either take finerenone or placebo, Importantly, the participants will also continue to take their regular SOC medicines.

The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, they will visit the study site at least 6 times.

The study team will:

  • collect blood and urine samples
  • check the participants' vital signs such as blood pressure and heart rate
  • do a physical examination including height and weight
  • check the participants' heart health by using an electrocardiogram (ECG)
  • do pregnancy tests in women of childbearing potential
03

Conditions studied

  • Chronic Kidney Disease
  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥18 years of age (or the legal age of consent according to local legislation) at the time of signing the .
  • Participants with Type 1 diabetes (T1D), i.e. T1D continuously treated with insulin, started within one year from diagnosis.

    • If the onset was after age 35, documentation of the presence of one or more of the following:

      • Circulating T1D-associated autoantibodies
      • Hospitalization for diabetic ketoacidosis
      • Plasma C-peptide below the limit of detection with standard assay (with concurrent blood glucose >100 mg/dl).
  • at Screening \<10% (central assessment).

    • Note: One reassessment is allowed for HbA1c during the Screening period in case the first measurement is missing/unreadable/invalid.
  • K+ ≤ 4.8 mmol/L at Screening (local assessment)
  • Participants with a clinical diagnosis of CKD and fulfilling both the criteria (central assessment):

    • ≥25 and \<90 mL/min/1.73 m\^2 using CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) 2009 formula at the Screening visit
    • UACR ≥200 mg/g (22.6 mg/mmol) to \<5000 mg/g (565 mg/mmol) at the Screening visit (geometric mean of the 3 measurements)
  • Participants on a stable (preferably without any change in the dosage for at least 4 weeks prior to the Screening visit) ACEI (Angiotensin-converting enzyme inhibitor) or ARB (Angiotensin receptor blocker) treatment.

Exclusion criteria

Exclusion Criteria:

  • Participant with T2D (Type 2 diabetes).
  • Participant with mean BP (Blood pressure) higher than 160/100 mmHg or mean systolic BP lower than 90 mmHg at the Screening visit
  • Symptomatic heart failure with reduced with class 1A indication for Mineralocorticoid receptor antagonists (MRAs).
  • Participants with current or previous (within 8 weeks prior to the Screening visit) treatment with a SGLT-2/-1 (Sodium-Glucose co-transporter-2/-1) inhibitor or GLP1 (Glucagon-like peptide-1) receptor agonist.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    Finerenone arm

    Participants with eGFR ≥25 to \<60 mL/min/1.73 m\^2 at Screening visit will take Finerenone Dose A. Participants with eGFR ≥60 mL/min/1.73 m\^2 at Screening visit will take Dose B. Up-titration and down-titration of study intervention will be based on local potassium and kidney function (eGFR) values. Treatment duration is 6 months.

    Drug: Finerenone

  • Placebo comparator
    Placebo arm

    Participants will take Finerenone matching placebo for 6 months.

    Other: Placebo

Interventions

  • Dose A, Dose B, oral

  • OtherPlacebo

    Oral

06

What researchers measure

Primary outcomes

  1. Change in UACR From Baseline (Ratio to Baseline) Over 6 Months

    UACR was assessed by a central laboratory at baseline, Month 3, and Month 6. The primary efficacy variable was change in UACR from baseline over 6 months, which was evaluated on the average of the Month 3 and Month 6 geometric mean UACR ratios to baseline within each treatment arm. A ratio to baseline below 1 indicates a reduction in UACR, with a smaller value indicating a better outcome. Both values were used to assess the treatment effect, with a ratio finerenone-versus-placebo below 1 indicating a better outcome with finerenone relative to placebo.

    Time frame: From baseline to Month 6

Secondary outcomes

  1. Number of Participants With Treatment-emergent AEs (TEAEs), Treatment-emergent SAEs (TESAEs)

    AE: An adverse event (AE) in this study is defined as any medical problem that the participants had during the study. This includes any new medical issue or a worsening of an existing condition that happens after the participant receives the study treatment, regardless of whether it is considered related to the study treatment. AEs that started or worsened after the first dose of study intervention up to 3 days after any temporary or permanent interruption of study intervention were considered as TEAEs; for the targeted AE reporting, non-serious AEs were not mandatory to be collected.

    Time frame: From the first dose of study intervention and up to 3 days after the last dose of study intervention, with a median treatment duration 6.07 months.

  2. Number of Participants With Treatment-emergent Hyperkalaemia

    Hyperkalemia (evaluated as the combined MedDRA Preferred terms blood potassium increased and hyperkalaemia) was an adverse event of special interest in this study and collected in the electronic case report form (eCRF).

    Time frame: From the first dose of study intervention and up to 3 days after the last dose of study intervention, with a median treatment duration 6.07 months.

07

Results

Posted Oct 27, 2026

Participant flow

79 recruiting centers, enrolling participants across Asia, Europe, and North America

Participant flow — Overall Study
MilestoneFinerenone GroupPlacebo Group
Started120122
Received treatment119122
Completed117112
Not completed310
Withdrew: Lost to follow-up20
Withdrew: Adverse event12
Withdrew: Death02
Withdrew: Participant decision04
Withdrew: Non-compliance with study schedule01
Withdrew: Protocol-specified withdrawal criterion met01

Outcome measures

PrimaryChange in UACR From Baseline (Ratio to Baseline) Over 6 Months

UACR was assessed by a central laboratory at baseline, Month 3, and Month 6. The primary efficacy variable was change in UACR from baseline over 6 months, which was evaluated on the average of the Month 3 and Month 6 geometric mean UACR ratios to baseline within each treatment arm. A ratio to baseline below 1 indicates a reduction in UACR, with a smaller value indicating a better outcome. Both values were used to assess the treatment effect, with a ratio finerenone-versus-placebo below 1 indicating a better outcome with finerenone relative to placebo.

Time frame:
From baseline to Month 6
Reported as:
Least squares mean · ratio to Baseline
Change in UACR From Baseline (Ratio to Baseline) Over 6 Months
ratio to BaselineFinerenone GroupPlacebo Group
Change in UACR From Baseline (Ratio to Baseline) Over 6 Months0.66 (0.60 to 0.73)0.88 (0.79 to 0.98)
Statistical analysis
  • Finerenone Group vs Placebo Group · mixed-effects model for repeated measure · p = 0.0001 · Ratio of ls means: 0.75 · 95% CI 0.65 to 0.87
SecondaryNumber of Participants With Treatment-emergent AEs (TEAEs), Treatment-emergent SAEs (TESAEs)

AE: An adverse event (AE) in this study is defined as any medical problem that the participants had during the study. This includes any new medical issue or a worsening of an existing condition that happens after the participant receives the study treatment, regardless of whether it is considered related to the study treatment. AEs that started or worsened after the first dose of study intervention up to 3 days after any temporary or permanent interruption of study intervention were considered as TEAEs; for the targeted AE reporting, non-serious AEs were not mandatory to be collected.

Time frame:
From the first dose of study intervention and up to 3 days after the last dose of study intervention, with a median treatment duration 6.07 months.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent AEs (TEAEs), Treatment-emergent SAEs (TESAEs)
ParticipantsFinerenone GroupPlacebo Group
Treatment-emergent AE5660
Treatment-emergent SAE1414
SecondaryNumber of Participants With Treatment-emergent Hyperkalaemia

Hyperkalemia (evaluated as the combined MedDRA Preferred terms blood potassium increased and hyperkalaemia) was an adverse event of special interest in this study and collected in the electronic case report form (eCRF).

Time frame:
From the first dose of study intervention and up to 3 days after the last dose of study intervention, with a median treatment duration 6.07 months.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Hyperkalaemia
ParticipantsFinerenone GroupPlacebo Group
Number of Participants With Treatment-emergent Hyperkalaemia124

Adverse events

Collected over TEAEs were collected from first dose up to 3 days after last dose of study intervention. The median treatment duration was 6.07 month. For all-cause mortality, deaths were collected from start of study (Informed consent signed) until last visit, over a median study duration of 7.11 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo2/122 (1.6%)14/122 (11.5%)3/122 (2.5%)
Finerenone0/119 (0%)14/119 (11.8%)10/119 (8.4%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventPlaceboFinerenone
Diabetic ketoacidosisMetabolism and nutrition disorders3/1222/119
HypoglycaemiaMetabolism and nutrition disorders3/1221/119
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/1222/119
HyperkalaemiaMetabolism and nutrition disorders0/1222/119
Acute kidney injuryRenal and urinary disorders0/1222/119
Atrial fibrillationCardiac disorders0/1221/119
Cardiac failureCardiac disorders0/1221/119
Myocardial ischaemiaCardiac disorders1/1221/119
Acute coronary syndromeCardiac disorders0/1221/119
Diabetic retinopathyEye disorders0/1221/119
Most frequent other events
Most frequent other events
EventPlaceboFinerenone
HyperkalaemiaMetabolism and nutrition disorders3/12210/119

Baseline characteristics

Age, Continuous
Age, Continuous(years)Finerenone GroupPlacebo GroupTotal
Mean51.25 ± 14.1751.88 ± 23.2051.57 ± 13.69
Sex: Female, Male
Sex: Female, Male(Participants)Finerenone GroupPlacebo GroupTotal
Female414384
Male7979158
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Finerenone GroupPlacebo GroupTotal
Pooled race — White8590175
Pooled race — Asian232548
Pooled race — Black9615
Pooled race — Other314
08

Study locations

79 sites
  • Southwest Kidney Institute, PLC - Suprise
    Surprise, Arizona 85374, United States
  • Stanford Endocrinology Clinic
    Stanford, California 94305, United States
  • Touro University California - Metabolic Research Center
    Vallejo, California 94592, United States
  • UHealth Diabetes Research Center - Miami
    Miami, Florida 33136, United States
  • AdventHealth Translational Research Institute
    Orlando, Florida 32804, United States
  • CTR Oakwater, LLC
    Orlando, Florida 32806, United States
  • Hanson Clinical Research Center, Inc.
    Port Charlotte, Florida 33952, United States
  • Jedidiah Clinical Research
    Tampa, Florida 33619, United States
  • Metabolic Research Institute, Inc.
    West Palm Beach, Florida 33401, United States
  • Grady Memorial Hospital - Endocrinology
    Atlanta, Georgia 30303, United States
  • Northwestern University | Feinberg School of Medicine - Division of Endocrinology, Metabolism and Molecular Medicine
    Chicago, Illinois 60611, United States
  • UChicago Medicine Kovler Diabetes Center
    Chicago, Illinois 60637, United States
  • Preventive Intervention Center - Endocrinology
    Iowa City, Iowa 52202, United States
  • Wichita Nephrology Group, PA
    Wichita, Kansas 67214, United States
  • Omega Clinical Research - Metairie
    Metairie, Louisiana 70006, United States
  • MedStar Health Research Institute
    Hyattsville, Maryland 20782, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • MU Health Care - University Hospital - Endocrinology
    Columbia, Missouri 65212, United States
  • Center for Advanced Medicine - Diabetes Center
    St Louis, Missouri 63110, United States
  • UNC Endocrinology, Diabetes, and Obesity Clinical Research Unit
    Chapel Hill, North Carolina 27514, United States
  • Physicians East, P.A.- W. H. Smith - Endocrinology
    Greenville, North Carolina 27834, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28401, United States
  • Cleveland Clinic - Main Campus - Endocrinology
    Cleveland, Ohio 44195, United States
  • OHSU Physicians Pavillion - Endocrinology
    Portland, Oregon 97239, United States
  • UT Health San Antonio - Medical Arts & Research Center - Endocrinology
    San Antonio, Texas 78229, United States
  • Consano Clinical Research, LLC.
    San Antonio, Texas 79231, United States
  • EVMS Strelitz Diabetes Center
    Norfolk, Virginia 23510, United States
  • Providence Medical Research Center
    Spokane Valley, Washington 99204, United States
  • Richmond Road Diagnostic and Treatment Centre | Clinical Trials Unit
    Calgary, Alberta T2T 5C7, Canada
  • Alberta Diabetes Institute | Clinical Research Unit (CRU)
    Edmonton, Alberta T6G 2E1, Canada
  • Toronto General Hospital - University Health Network, Renal Physiology laboratory
    Toronto, Ontario M5G 2C4, Canada
  • Research Institute of the McGill University Health Centre | McConnell Centre for Innovative Medicine
    Montreal, Quebec H4A 3J1, Canada
  • Centre hospitalier universitaire de Québec (CHUQ) | Cardiology
    Québec, Quebec G1R 2J6, Canada
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
  • Southern Medical University - Nanfang Hospital (Southern Hospital)
    Guangzhou, Guangdong 510515, China
  • Zhongshan People's Hospital
    Zhongshan, Guangdong 528499, China
  • The 4th Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The Central Hospital of Wuhan, Tongji Medl Collg Huazhong...
    Wuhan, Hubei 430014, China
  • Huai'an First People's Hospital, Nanjing Medical University
    Huai'an, Jiangsu 223300, China
  • Nanjing Medical University (NMU) - The Second Affiliated Hospital
    Nanjing, Jiangsu 210011, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212001, China
  • Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital (Shanghai First People's Hospital) - Northern Location
    Shanghai, Shanghai Municipality 200080, China
  • Central Hospital of Minhang District, Shanghai
    Shanghai, Shanghai Municipality 201199, China
  • Zhongshan Hospital Fudan University, Qingpu Branch
    Shanghai, Shanghai Municipality 201700, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030032, China
  • Steno Diabetes Center Copenhagen | Herlev - Clinical and Translational Research Department
    Herlev, Capital Region / Region Hovedstaden 2730, Denmark
  • Capital Region | Nordsjaellands Hospital - Hillerod - Endocrinology Ambulatory Research Unit
    Hillerød, Capital Region / Region Hovedstaden 3400, Denmark
  • Region Midtjylland | Regionshospitalet Godstrup - Nephrology Department
    Herning, Central Denmark Region / Region Midtjylland 7400, Denmark
  • Region Nordjylland | Steno Diabetes Center Nordjylland - Endocrinology Department
    Gistrup, North Denmark Region / Region Nordjylland 9260, Denmark
  • Hospital of South West Jutland | Department of Endocrinology Research
    Esbjerg, Region of Southern Denmark / Region Syddanmark 6700, Denmark
  • Odense University Hospital | Odense - Endocrinology Department
    Odense, Region of Southern Denmark / Region Syddanmark 5000, Denmark
  • Ruhr-Universitaet Bochum - Herz und Diabeteszentrum NRW (Heart and Diabetes Center)
    Bad Oeynhausen, North Rhine-Westphalia 32545, Germany
  • InnoDiab Forschung GmbH
    Essen, North Rhine-Westphalia 45136, Germany
  • ASST Papa Giovanni XXIII | Ospedale di Bergamo - SC Malattie Endocrine-Diabetologia
    Bergamo, 24127, Italy
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Endocrinologia e prevenzione e cura del diabete
    Bologna, 40138, Italy
  • Azienda Sanitaria Locale di Chieri | TO5 - SC Diabetologia Territoriale
    Chieri, 10023, Italy
  • Università degli Studi "G. D'Annunzio" di Chieti - Endocrinologia
    Chieti, 66100, Italy
  • Careggi University Hospital - Diabetologia e Malattie del Metabolismo
    Florence, 50134, Italy
  • IRCCS Ospedale San Raffaele | Diabetologia Department - Cardio-Metabolic and Clinica Trials Unit
    Milan, 20132, Italy
  • ASST Santi Paolo e Carlo | San Paolo Hospital - Haemostasis and Thrombosis Department
    Milan, 20142, Italy
  • ASST Fatebenefratelli Sacco _Ospedale Sacco - Malattie Endocrine e Diabetologia
    Milan, 20157, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOSD Diabetologia
    Roma, 00168, Italy
  • Anam Hospital | Endocrinology and Metabolism
    Seongbuk, Seoul 02841, South Korea
  • Seoul National University Hospital | Endocrinology and Metabolism
    Seoul, Seoul 03080, South Korea
  • Severance Hospital | Endocrinology and Metabolism
    Seoul, Seoul 03722, South Korea
  • Asan Medical Center | Endocrinology and Metabolism
    Seoul, Seoul 05505, South Korea
  • Complexo Hospitalario Universitario A Coruna | Endocrinologia
    A Coruña, A Coruña 15006, Spain
  • Hospital Clinic De Barcelona | Endocrinologia
    Barcelona, Barcelona 08036, Spain
  • Hospital General Universitario Gregorio Maranon | Endocrinologia
    Madrid, Madrid 28007, Spain
  • Hospital Universitario Puerta De Hierro De Majadahonda | Endocrinologia
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitario Virgen De La Victoria | Endocrinologia
    Málaga, Málaga 29010, Spain
  • Hospital Nisa Sevilla Aljarafe | Endocrinologia
    Castilleja de la Cuesta, Sevilla 41950, Spain
  • Southmead Hospital | Clinical Research Centre
    Bristol, Bristol BS10 5NB, United Kingdom
  • Royal Derby Hospital | Renal Research
    Derby, Derbyshire DE22 3NE, United Kingdom
  • Royal London Hospital | Nephrology
    London, Greater London E1 1BB, United Kingdom
  • Wythenshawe Hospital | Clinical Research Facility
    Manchester, Greater Manchester M23 9LT, United Kingdom
  • Glasgow Royal Infirmary | Renal Unit
    Glasgow, Scotland G4 0SF, United Kingdom
  • University Hospital of Wales | Nephrology and Transplant
    Cardiff, Wales CF14 4XW, United Kingdom
  • Manor Hospital | Nephrology
    Walsall, West Midlands WS2 9PS, United Kingdom
09

References and documents

Publications

  • Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Groop PH, Ji L, Jongs N, Mathieu C, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Brinker M, Scheerer MF, Russell J, Schloemer P, McGill JB; FINE-ONE Investigators. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med. 2026 Mar 5;394(10):947-957. doi: 10.1056/NEJMoa2512854. PubMed 41780000 ↗
  • Kugathasan L, Aronson Y, Sridhar VS, Ni H, Ouimet JP, Limonte CP, Sarma S, Cherney DZI. Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease. Expert Rev Clin Immunol. 2025 Aug;21(8):1113-1134. doi: 10.1080/1744666X.2025.2537446. Epub 2025 Jul 24. PubMed 40693871 ↗
  • Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Ji L, Mathieu C, Groop PH, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Scott C, Edfors R, Scheerer MF, Kolkhof P, McGill JB. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res Clin Pract. 2023 Oct;204:110908. doi: 10.1016/j.diabres.2023.110908. Epub 2023 Oct 5. PubMed 37805000 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Aug 2025, 17 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 17 months is below that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2023
First posted
Jun 13, 2023
StartActual
Feb 26, 2024
Primary completionActual
Aug 20, 2025
CompletionActual
Sep 15, 2025
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Sites
45 sites added, 46 sites removed
Show 45 added (8 China, 7 United Kingdom, 6 United States, 6 Denmark, 6 Spain, 4 Canada, 4 South Korea, 3 Italy, 1 Germany)
  • UHealth Diabetes Research Center - Miami · Miami, United States
  • CTR Oakwater, LLC · Orlando, United States
  • Wichita Nephrology Group, PA · Wichita, United States
  • Omega Clinical Research - Metairie · Metairie, United States
  • Center for Advanced Medicine - Diabetes Center · St Louis, United States
  • Cleveland Clinic - Main Campus - Endocrinology · Cleveland, United States
  • Richmond Road Diagnostic and Treatment Centre | Clinical Trials Unit · Calgary, Canada
  • Alberta Diabetes Institute | Clinical Research Unit (CRU) · Edmonton, Canada
  • Research Institute of the McGill University Health Centre | McConnell Centre for Innovative Medicine · Montreal, Canada
  • Centre hospitalier universitaire de Québec (CHUQ) | Cardiology · Québec, Canada
  • Peking University People's Hospital · Beijing, China
  • Southern Medical University - Nanfang Hospital (Southern Hospital) · Guangzhou, China
  • Huai'an First People's Hospital, Nanjing Medical University · Huai'an, China
  • Nanjing Medical University (NMU) - The Second Affiliated Hospital · Nanjing, China
  • Affiliated Hospital of Jiangsu University · Zhenjiang, China
  • Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital (Shanghai First People's Hospital) - Northern Location · Shanghai, China
  • Central Hospital of Minhang District, Shanghai · Shanghai, China
  • Zhongshan Hospital Fudan University, Qingpu Branch · Shanghai, China
  • Steno Diabetes Center Copenhagen | Herlev - Clinical and Translational Research Department · Herlev, Denmark
  • Capital Region | Nordsjaellands Hospital - Hillerod - Endocrinology Ambulatory Research Unit · Hillerød, Denmark
  • Region Midtjylland | Regionshospitalet Godstrup - Nephrology Department · Herning, Denmark
  • Region Nordjylland | Steno Diabetes Center Nordjylland - Endocrinology Department · Gistrup, Denmark
  • Hospital of South West Jutland | Department of Endocrinology Research · Esbjerg, Denmark
  • Odense University Hospital | Odense - Endocrinology Department · Odense, Denmark
  • Ruhr-Universitaet Bochum - Herz und Diabeteszentrum NRW (Heart and Diabetes Center) · Bad Oeynhausen, Germany
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Endocrinologia e prevenzione e cura del diabete · Bologna, Italy
  • Careggi University Hospital - Diabetologia e Malattie del Metabolismo · Florence, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOSD Diabetologia · Roma, Italy
  • Anam Hospital | Endocrinology and Metabolism · Seongbuk, South Korea
  • Seoul National University Hospital | Endocrinology and Metabolism · Seoul, South Korea
  • …and 15 more on the registry record
Show 46 removed
  • UHealth Diabetes Research Center · Miami, United States
  • Elixia Central Florida · Orlando, United States
  • Wichita Nephrology Group Pa · Wichita, United States
  • Diabetes & Metabolism Associates · Metairie, United States
  • Washington University School of Medicine in St. Louis · St Louis, United States
  • Cleveland Clinic - Main Campus · Cleveland, United States
  • Richmond Road Diagnostic and Treatment Centre - Clinical Trials Unit(RRDTC) · Calgary, Canada
  • Alberta Diabetes Institute - Clinical Research Unit (CRU) · Edmonton, Canada
  • Centre de Recherche Clinique de Laval · Laval, Canada
  • McGill University Health Centre (MUHC) - Research Institute (RI) - McConnell Centre for Innovative Medicine (CIM) · Montreal, Canada
  • Affiliated Hospital of Jiangsu University · JiangSu, China
  • Peking University People's Hospital · Beijing, China
  • Southern Medical University - Nanfang Hospital (Southern Hospital) · Guangzhou, China
  • Huai'an First People's Hospital, Nanjing Medical University · Huai'an, China
  • Nanjing Medical University (NMU) - The Second Affiliated Hospital · Nanjing, China
  • Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital (Shanghai First People's Hospital) - Northern Location · Shanghai, China
  • Central Hospital of Minhang District, Shanghai · Shanghai, China
  • Zhongshan Hospital Fudan University, Qingpu Branch · Shanghai, China
  • Hospital of South West Jutland | Department of Endocrinology Research · Esbjerg, Denmark
  • Region Nordjylland | Steno Diabetes Center Nordjylland - Endocrinology Department · Gistrup, Denmark
  • Steno Diabetes Center Copenhagen | Herlev - Clinical and Translational Research Department · Herlev, Denmark
  • Region Midtjylland | Regionshospitalet Godstrup - Nephrology Department · Herning, Denmark
  • Capital Region | Nordsjaellands Hospital - Hillerod - Endocrinology Ambulatory Research Unit · Hillerød, Denmark
  • Odense University Hospital | Odense - Endocrinology Department · Odense, Denmark
  • Ruhr-Universitaet Bochum - Herz und Diabeteszentrum NRW (Heart and Diabetes Center) · Bad Oeynhausen, Germany
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Endocrinologia e prevenzione e cura del diabete · Bologna, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOSD Diabetologia · Rome, Italy
  • Careggi University Hospital - Diabetologia e Malattie del Metabolismo · Florence, Italy
  • Severance Hospital, Yonsei University Health System · Seoul, South Korea
  • Asan Medical Center - Oncology Department · Seoul, South Korea
  • …and 16 more on the registry record
Oct 27, 2026
Enrollment
241→242
Oct 27, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Change in Urinary albumin-to-creatinine ratio (UACR)Now Change in UACR From Baseline (Ratio to Baseline) Over 6 MonthsTime frame: From baseline up to 6 months → From baseline to Month 6
Oct 27, 2026
Documents
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedNumber of participants with treatmentParticipants With Treatment-emergent adverse eventsAEs (TEAEs), Treatment-emergent serious adverse eventSAEs (TESAEs)Time frame: From baseline up to 7 months → From the first dose of study intervention and up to 3 days after the last dose of study intervention, with a median treatment duration 6.07 months.
  • EditedNumber of participants withParticipants With Treatment-emergent HyperkalaemiaTime frame: From baseline up to 7 months → From the first dose of study intervention and up to 3 days after the last dose of study intervention, with a median treatment duration 6.07 months.
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    45 sites added, 46 sites removed
    Show 45 added (8 China, 7 United Kingdom, 6 United States, 6 Denmark, 6 Spain, 4 Canada, 4 South Korea, 3 Italy, 1 Germany)
    • UHealth Diabetes Research Center - Miami · Miami, United States
    • CTR Oakwater, LLC · Orlando, United States
    • Wichita Nephrology Group, PA · Wichita, United States
    • Omega Clinical Research - Metairie · Metairie, United States
    • Center for Advanced Medicine - Diabetes Center · St Louis, United States
    • Cleveland Clinic - Main Campus - Endocrinology · Cleveland, United States
    • Richmond Road Diagnostic and Treatment Centre | Clinical Trials Unit · Calgary, Canada
    • Alberta Diabetes Institute | Clinical Research Unit (CRU) · Edmonton, Canada
    • Research Institute of the McGill University Health Centre | McConnell Centre for Innovative Medicine · Montreal, Canada
    • Centre hospitalier universitaire de Québec (CHUQ) | Cardiology · Québec, Canada
    • Peking University People's Hospital · Beijing, China
    • Southern Medical University - Nanfang Hospital (Southern Hospital) · Guangzhou, China
    • Huai'an First People's Hospital, Nanjing Medical University · Huai'an, China
    • Nanjing Medical University (NMU) - The Second Affiliated Hospital · Nanjing, China
    • Affiliated Hospital of Jiangsu University · Zhenjiang, China
    • Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital (Shanghai First People's Hospital) - Northern Location · Shanghai, China
    • Central Hospital of Minhang District, Shanghai · Shanghai, China
    • Zhongshan Hospital Fudan University, Qingpu Branch · Shanghai, China
    • Steno Diabetes Center Copenhagen | Herlev - Clinical and Translational Research Department · Herlev, Denmark
    • Capital Region | Nordsjaellands Hospital - Hillerod - Endocrinology Ambulatory Research Unit · Hillerød, Denmark
    • Region Midtjylland | Regionshospitalet Godstrup - Nephrology Department · Herning, Denmark
    • Region Nordjylland | Steno Diabetes Center Nordjylland - Endocrinology Department · Gistrup, Denmark
    • Hospital of South West Jutland | Department of Endocrinology Research · Esbjerg, Denmark
    • Odense University Hospital | Odense - Endocrinology Department · Odense, Denmark
    • Ruhr-Universitaet Bochum - Herz und Diabeteszentrum NRW (Heart and Diabetes Center) · Bad Oeynhausen, Germany
    • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Endocrinologia e prevenzione e cura del diabete · Bologna, Italy
    • Careggi University Hospital - Diabetologia e Malattie del Metabolismo · Florence, Italy
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOSD Diabetologia · Roma, Italy
    • Anam Hospital | Endocrinology and Metabolism · Seongbuk, South Korea
    • Seoul National University Hospital | Endocrinology and Metabolism · Seoul, South Korea
    • …and 15 more on the registry record
    Show 46 removed
    • UHealth Diabetes Research Center · Miami, United States
    • Elixia Central Florida · Orlando, United States
    • Wichita Nephrology Group Pa · Wichita, United States
    • Diabetes & Metabolism Associates · Metairie, United States
    • Washington University School of Medicine in St. Louis · St Louis, United States
    • Cleveland Clinic - Main Campus · Cleveland, United States
    • Richmond Road Diagnostic and Treatment Centre - Clinical Trials Unit(RRDTC) · Calgary, Canada
    • Alberta Diabetes Institute - Clinical Research Unit (CRU) · Edmonton, Canada
    • Centre de Recherche Clinique de Laval · Laval, Canada
    • McGill University Health Centre (MUHC) - Research Institute (RI) - McConnell Centre for Innovative Medicine (CIM) · Montreal, Canada
    • Affiliated Hospital of Jiangsu University · JiangSu, China
    • Peking University People's Hospital · Beijing, China
    • Southern Medical University - Nanfang Hospital (Southern Hospital) · Guangzhou, China
    • Huai'an First People's Hospital, Nanjing Medical University · Huai'an, China
    • Nanjing Medical University (NMU) - The Second Affiliated Hospital · Nanjing, China
    • Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital (Shanghai First People's Hospital) - Northern Location · Shanghai, China
    • Central Hospital of Minhang District, Shanghai · Shanghai, China
    • Zhongshan Hospital Fudan University, Qingpu Branch · Shanghai, China
    • Hospital of South West Jutland | Department of Endocrinology Research · Esbjerg, Denmark
    • Region Nordjylland | Steno Diabetes Center Nordjylland - Endocrinology Department · Gistrup, Denmark
    • Steno Diabetes Center Copenhagen | Herlev - Clinical and Translational Research Department · Herlev, Denmark
    • Region Midtjylland | Regionshospitalet Godstrup - Nephrology Department · Herning, Denmark
    • Capital Region | Nordsjaellands Hospital - Hillerod - Endocrinology Ambulatory Research Unit · Hillerød, Denmark
    • Odense University Hospital | Odense - Endocrinology Department · Odense, Denmark
    • Ruhr-Universitaet Bochum - Herz und Diabeteszentrum NRW (Heart and Diabetes Center) · Bad Oeynhausen, Germany
    • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Endocrinologia e prevenzione e cura del diabete · Bologna, Italy
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOSD Diabetologia · Rome, Italy
    • Careggi University Hospital - Diabetologia e Malattie del Metabolismo · Florence, Italy
    • Severance Hospital, Yonsei University Health System · Seoul, South Korea
    • Asan Medical Center - Oncology Department · Seoul, South Korea
    • …and 16 more on the registry record
    Enrollment 241→242
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Change in Urinary albumin-to-creatinine ratio (UACR)Now Change in UACR From Baseline (Ratio to Baseline) Over 6 MonthsTime frame: From baseline up to 6 months → From baseline to Month 6
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedNumber of participants with treatmentParticipants With Treatment-emergent adverse eventsAEs (TEAEs), Treatment-emergent serious adverse eventSAEs (TESAEs)Time frame: From baseline up to 7 months → From the first dose of study intervention and up to 3 days after the last dose of study intervention, with a median treatment duration 6.07 months.
    • EditedNumber of participants withParticipants With Treatment-emergent HyperkalaemiaTime frame: From baseline up to 7 months → From the first dose of study intervention and up to 3 days after the last dose of study intervention, with a median treatment duration 6.07 months.
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05901831
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 13, 2023
Start date
Feb 26, 2024
Primary completion
Aug 20, 2025
Completion
Sep 15, 2025
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion